Matthew J. Marton

25.1k citations

45 papers · 10.6k indexed · 4 hit papers · h-index 18

Molecular Biology top 0.5%
Cancer Research top 0.5%
Oncology top 1%
Genetics top 1%
Pulmonary and Respiratory Medicine top 5%

Co-authors: Hongyue Dai Stephen Friend Yudong D. He Laura van ‘t Veer René Bernards Mao Mao Ron Kerkhoven K van der Kooy
Topics: Cancer Genomics and Diagnostics (11 papers)Cancer Immunotherapy and Biomarkers (10 papers)Molecular Biology Techniques and Applications (7 papers)
Cited by: Cancer Research Molecular Biology Oncology
Journals: Nature Science Journal of Biological Chemistry
Partner nations: United States Denmark United Kingdom

In The Last Decade

Matthew J. Marton

42 papers receiving 10.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gene expression profiling predicts clinical outcome of breast cancer

2002 7.0k citations Hongyue Dai, Yudong D. He et al. profile →
Signaling and Circuitry of Multiple MAPK Pathways Revealed by a Matrix of Global Gene Expression Profiles

2000 691 citations Christopher J. Roberts, Bryce Nelson et al. profile →
Transcriptional Profiling Shows that Gcn4p Is a Master Regulator of Gene Expression during Amino Acid Starvation in Yeast

2001 598 citations Michael R. Meyer, David Slade et al. Molecular and Cellular Biology profile →
Drug target validation and identification of secondary drug target effects using DNA microarrays

1998 479 citations Matthew J. Marton, Joseph L. DeRisi et al. Nature Medicine profile →

Peers

Countries citing papers authored by Matthew J. Marton

Since Specialization

Citations

This map shows the geographic impact of Matthew J. Marton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew J. Marton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew J. Marton more than expected).

Fields of papers citing papers by Matthew J. Marton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew J. Marton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew J. Marton. The network helps show where Matthew J. Marton may publish in the future.

Co-authorship network of co-authors of Matthew J. Marton

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew J. Marton. A scholar is included among the top collaborators of Matthew J. Marton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew J. Marton. Matthew J. Marton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer 2024 ·Gynecologic Oncology ·(unknown),Ping Qiu,Jared Lunceford,(unknown),Răzvan Cristescu,Li Liu,(unknown),Sven Bilke,John Day,Kirsten M. Timms,Wilko Weichert,Matthew J. Marton	6
2	Concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test 2022 ·BMC Cancer ·Răzvan Cristescu,Xiao Qiao Liu,Gladys Arreaza,Cai Chen,Andrew Albright,Ping Qiu,Matthew J. Marton	5
3	Assessing homologous recombination deficiency (HRD) in ovarian cancer: Optimizing concordance of the regulatory-approved companion diagnostic and a next-generation sequencing (NGS) assay kit. 2022 ·Journal of Clinical Oncology ·Wilko Weichert,(unknown),Jared Lunceford,(unknown),(unknown),Răzvan Cristescu,Li Liu,(unknown),Kirsten M. Timms,Matthew J. Marton	4
4	Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer 2020 ·International Journal of Gynecological Cancer ·Estrid Høgdall,Claus Høgdall,(unknown),Wei Zhou,Lingkang Huang,Matthew J. Marton,Stephen J. O’Keefe,Michael Busch-Sørensen,(unknown),(unknown),(unknown),Lotte Nedergaard,Torben Steiniche	8
5	Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS Assays 2019 ·Scientific Reports ·Ping Qiu,Christian Poehlein,Matthew J. Marton,Omar Laterza,Diane Levitan	41
6	Development of a PCR Assay to Detect Low Level Trypanosoma cruzi in Blood Specimens Collected with PAXgene Blood DNA Tubes for Clinical Trials Treating Chagas Disease 2016 ·PLoS neglected tropical diseases ·Bo Wei,Lei Chen,Miho Kibukawa,(unknown),Hetty Waskin,Matthew J. Marton	12
7	Analytical Validation of AmpliChip p53 Research Test for Archival Human Ovarian FFPE Sections 2015 ·PLoS ONE ·Matthew J. Marton,(unknown),(unknown),(unknown),Jonathan D. Cheng	3
8	Navigating the Rapids: The Development of Regulated Next-Generation Sequencing-Based Clinical Trial Assays and Companion Diagnostics 2014 ·Frontiers in Oncology ·Saumya Pant,Russell Weiner,Matthew J. Marton	50
9	Development and Validation of a Clinical Trial Patient Stratification Assay That Interrogates 27 Mutation Sites in MAPK Pathway Genes 2013 ·PLoS ONE ·Ken C. N. Chang,Stefan Galuska,Russell Weiner,Matthew J. Marton	1
10	Refined anatomical isolation of functional sleep circuits exhibits distinctive regional and circadian gene transcriptional profiles 2009 ·Brain Research ·Christopher J. Winrow,Keith Q. Tanis,Alison Rigby,(unknown),Kyle Serikawa,(unknown),George Tokiwa,Matthew J. Marton,David J. Stone,Kenneth S. Koblan,John J. Renger	13
11	Development of a microarray platform for FFPET profiling: application to the classification of human tumors 2009 ·Journal of Translational Medicine ·Sven Duenwald,Mingjie Zhou,Yanqun Wang,Serguei Lejnine,Amit Kulkarni,(unknown),Ryan Smith,John C. Castle,George Tokiwa,Bernard M. Fine,Hongyue Dai,Thomas L. Fare,Matthew J. Marton	14
12	Functional Interactions between Yeast Translation Eukaryotic Elongation Factor (eEF) 1A and eEF3 2003 ·Journal of Biological Chemistry ·Monika Anand,Kalpana Chakraburtty,Matthew J. Marton,Alan G. Hinnebusch,Terri Goss Kinzy	57
13	Effects of Atmospheric Ozone on Microarray Data Quality 2003 ·Analytical Chemistry ·Thomas L. Fare,Ernest M. Coffey,Hongyue Dai,Yudong D. He,(unknown),K. Kilian,(unknown),Eric LeProust,Matthew J. Marton,Michael R. Meyer,Roland Stoughton,George Tokiwa,Yanqun Wang	166
14	Identification of genes over-expressed in small cell lung carcinoma using suppression subtractive hybridization and cDNA microarray expression analysis 2002 ·Oncogene ·Chaitanya Bangur,(unknown),Li-Qun Fan,Matthew J. Marton,Michael R. Meyer,Tongtong Wang	54
15	Role of scaffolds in MAP kinase pathway specificity revealed by custom design of pathway-dedicated signaling proteins 2001 ·Current Biology ·(unknown),(unknown),Bryce Nelson,Timothy R. Hughes,Matthew J. Marton,Christopher J. Roberts,(unknown),Peter M. Pryciak	94
16	Widespread aneuploidy revealed by DNA microarray expression profiling 2000 ·Nature Genetics ·Timothy R. Hughes,Chris Roberts,Hongyue Dai,Allan R. Jones,Markus R. Meyer,David Slade,Julja Burchard,Sally Dow,Teresa R. Ward,M. Kidd,Stephen Friend,Matthew J. Marton	384
17	Drug target validation and identification of secondary drug target effects using DNA microarraysbreakdown → 1998 ·Nature Medicine ·Matthew J. Marton,Joseph L. DeRisi,(unknown),Vishwanath R. Iyer,Michael R. Meyer,Christopher J. Roberts,Roland Stoughton,Julja Burchard,David Slade,Hongyue Dai,Douglas E. Bassett,Leland H. Hartwell,Patrick O. Brown,Stephen Friend	479
18	Interaction between the Retinoid X Receptor and Transcription Factor IIB Is Ligand-dependent in Vivo 1998 ·Journal of Biological Chemistry ·Gary M. Leong,(unknown),Matthew J. Marton,Jorge C. G. Blanco,I‐Ming Wang,Ronda J. Rolfes,Keiko Ozato,James H. Segars	12
19	Evidence that GCN1 and GCN20, Translational Regulators of GCN4 , Function on Elongating Ribosomes in Activation of eIF2α Kinase GCN2 1997 ·Molecular and Cellular Biology ·Matthew J. Marton,Carlos R. Vázquez de Aldana,Hongfang Qiu,Kalpana Chakraburtty,Alan G. Hinnebusch	184
20	COUNTERACTION TO AND PREVENTION OF, DIFFERENT ANXIETY TYPES IN ASTHMATIC, CARDIAC NEUROTIC AND HYPERTENSIVE CHILDREN. 1964 ·PubMed ·(unknown),Matthew J. Marton	2

About Matthew J. Marton

Matthew J. Marton is a scholar working on Cancer Research, Oncology and Molecular Biology, having authored 45 papers that have together received 10.6k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (11 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Molecular Biology Techniques and Applications (7 papers). The work is most often cited by research in Cancer Research (2.8k citations), Molecular Biology (7.5k citations) and Oncology (2.5k citations). Matthew J. Marton has collaborated with scholars based in United States, Denmark and United Kingdom. Frequent co-authors include Hongyue Dai, Stephen Friend, Yudong D. He, Laura van ‘t Veer, René Bernards, Mao Mao, Ron Kerkhoven, K van der Kooy, Hans Peterse and George J. Schreiber. Their work appears in journals such as Nature, Science and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact